- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Clarius Launches Dual-Array Handheld Whole-Body Ultrasound Scanner
Combining phased and linear arrays on a single head, the Clarius PAL HD3 ultrasound device was unveiled at the recent American College of Emergency Physicians (ACEP) Scientific Assembly conference.
Featuring the imaging processing technology of traditional ultrasound systems, the newly launched Clarius PAL HD3 handheld ultrasound device reportedly offers an array of features to facilitate real-time, whole-body imaging at a patient’s bedside.
Showcased at the recent American College of Emergency Physicians (ACEP) Scientific Assembly in Philadelphia, the FDA-cleared ultrasound device provides high-resolution images from superficial anatomy down to 40 cm of depth, according to Clarius.
The company said other key features of the Clarius PAL HD3 device include advanced eight beamformer image processing technology (in comparison to one or two beamformer processing for the majority of other handheld ultrasound devices), and easy access to phased and linear arrays on a single head.
"The Clarius PAL is a big breakthrough for Clarius and for clinical ultrasound in general. Integrating the phased and linear array means you only need one transducer for 95 to 99% of the studies at the bedside," said Tom Cook, M.D., an emergency physician, and ultrasound educator who practices in Columbia, South Carolina.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
